SLXN 10-Q: SEC filing
Silexion Therapeutics Corp
Filed with the SEC on · accession 0001178913-26-005201
SLXN filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -17.6% by the first close after the filing.
Summary of the filing
Silexion Therapeutics Corp filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing financial results, a 1-for-10 reverse share split, and various financing activities including at-the-market offerings and warrant inducement agreements.
Key details
How SLXN stock reacted
Close before
$3.23
Nov 11, 2026
First close after
-17.65%
$2.66
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for SLXN, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SLXN?
Click hereFrequently asked questions
What did SLXN file with the SEC on Nov 12, 2026?
SLXN filed a 10-Q (SEC filing). Silexion Therapeutics Corp filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing financial results, a 1-for-10 reverse share split, and various financing activities including at-the-market offerings and warrant inducement agreements.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did SLXN stock react to this filing?
SLXN closed at $3.23 before the filing and $2.66 on Nov 12, 2026 (-17.65%).
Other SLXN SEC filings
- EFFECT · Shelf registrationNov 9, 2026
- 8-K · Stock splitNov 9, 2026
- S-3 · Shelf registrationOct 28, 2026
- 8-K · SEC filingOct 26, 2026
- DEF 14A · Stock splitOct 5, 2026
- 8-K · Fda approvalSep 30, 2026
- 424B3 · Secondary offeringSep 29, 2026
- 8-K · SEC filingSep 29, 2026
- SCHEDULE 13D/A · Activist campaignSep 28, 2026
- 8-K · Fda approvalSep 28, 2026
Get alerts when SLXN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days